Data Integrity and Form 483 or Warning Letters
April 28, 2014 / /
Data integrity is an essential component of both clinical and nonclinical research conducted under the supervision of the Food and Drug Administration.
Posted in FDA Enforcement, FDA News Update and tagged with 21 CFR, 58, 483, BIMO, Bioresearch, CBER, CDER, CPGM, FORM, GUIDANCE, LETTER, Monitoring, OBSERVATIONS, PROGRAM, Part, STUDY, Subpart, WARNING, clinical, compliance, data, integrity, manual, non, pre, research, studies
Are you in trouble with the FDA?
Don’t panic — you’ve got backup. Download 5 Tips to Help You Navigate FDA Enforcement and learn how to resolve the situation right now.